ISRCTN12415112 https://doi.org/10.1186/ISRCTN12415112

The Renin Angiotensin System in Essential Hypertension

Submission date	Recruitment status	[ ] Prospectively registered
29/09/2006	No longer recruiting	[ ] Protocol
Registration date	**Overall study status**	[ ] Statistical analysis plan
29/09/2006	Completed	[ ] Results
Last Edited	**Condition category**	[ ] Individual participant data
11/10/2017	Circulatory System	[ ] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr David New

Contact details
Blood Pressure Unit
Dept of Physiological Medicine
St George's Hospital Medical School
Cranmer Terrace
London
United Kingdom
SW17 0RE

Additional identifiers

Protocol serial number
N0236102657

Study information

Scientific Title
The Renin Angiotensin System in Essential Hypertension

Study objectives

To determine and compare the effects of enalapril on sodium balance, atrial pressure and the renin angiotensin aldosterone system in humans.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised crossover trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Cardiovascular: Essential hypertension

Interventions
Randomised crossover trial

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
This research is based on the increasing evidence that blockade of the renin-angiotensin-aldosterone system has benefits additional to a fall in blood pressure. There are two major ways of blocking the renin-angiotensin system (RAS), either by inhibiting the enzyme that generates angiotensin II or by blocking the angiotensin receptor, that medicates most of the actions of angiotensin II on its target tissues.
The original and existing aim of this study is to compare the effects of enalapril, an angiotensin converting enzyme inhibitor, against candesartan, a potent and specific angiotensin II receptor blocker, in both normotensive and hypertensive subjects on a normal and moderate sodium restricted diet. Assessment of the contribution of the RAS to blood pressure control and of the mechanism whereby blood pressure falls, will provide important information about the maintenance of blood pressure.

Key secondary outcome(s))
Not provided at time of registration

Completion date
30/09/2005

Eligibility

Key inclusion criteria
11 subjects and 11 controls

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Does not meet inclusion criteria

Date of first enrolment
03/12/2001

Date of final enrolment
30/09/2005

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
St George's Hospital Medical School
London
United Kingdom
SW17 0RE

Sponsor information

Organisation
Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
St George's Healthcare NHS Trust (UK)

Funder Name
No External Funding

Funder Name
NHS R&D Support Funding (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration